Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

NAD+ iconNAD+Small moleculeNo amino acid sequence. Icon reflects category theme only.

NAD+

Beginner tier: 100 mg, 2x/week · community consensus

Anti-AgingResearch
Not measured half-life·Injection

Also known as: NAD, NAD+, Coenzyme I

Plasma NAD+ levels jumped 398% above baseline after a single six-hour IV infusion in a 2019 pilot study [1]. NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in every living cell, powering over 500 enzymatic reactions tied to energy production, DNA repair, and sirtuin activation. The catch: controlled human trial data for general anti-aging use remains thin, with most wellness claims resting on mechanistic rationale rather than large RCTs. Injectable NAD+ has found its strongest clinical footing in addiction recovery, where a 10-day IV protocol dropped substance cravings from 5.9 to 0.22 on a 10-point scale in 50 patients [2].

What Is NAD+?

A 398% spike in plasma levels after one six-hour drip. That single data point from a 2019 pilot study [1] turned NAD+ (Nicotinamide Adenine Dinucleotide, CAS 53-84-9) from a biochemistry footnote into one of the most discussed molecules in longevity circles.

NAD+ sits at the center of cellular energy metabolism. It shuttles electrons through glycolysis, the tricarboxylic acid cycle, and oxidative phosphorylation to produce ATP. It also feeds three enzyme families that control aging: sirtuins (SIRT1 through SIRT7), PARPs for DNA repair, and CD38, an ectoenzyme whose activity rises with age and is now considered a primary driver of NAD+ decline. Between ages 40 and 60, cellular NAD+ drops roughly 50%.

The practical question is whether restoring those levels from the outside actually changes outcomes. For addiction recovery, the answer looks promising. The BR+NAD protocol (500 to 1,500 mg/day IV over 10 days) reduced craving scores from 5.9 to 0.22 in 50 substance use disorder patients [2]. For general wellness and anti-aging, the community runs ahead of the science. Hundreds of threads across r/Nootropics, r/longevity, and r/Peptides consistently report improved energy, reduced brain fog, and better exercise recovery with subcutaneous dosing at 100 to 250 mg twice weekly. A 2024 systematic review [3] confirmed safety across clinical conditions but called the efficacy evidence "heterogeneous." Science has not refuted the wellness case; data simply lags community adoption.

How NAD+ Works

NAD+ is a central metabolic coenzyme in oxidized (NAD+) and reduced (NADH) forms. It passes electrons through three energy-generating pathways: glycolysis, the tricarboxylic acid cycle, and the electron transport chain. Without adequate NAD+, ATP production slows at every step.

Beyond energy, NAD+ is the required substrate for sirtuins (SIRT1 through SIRT7), a family of deacetylases that regulate gene expression, mitochondrial biogenesis, and inflammatory signaling. SIRT1 and SIRT3 are the two most studied in longevity research. When NAD+ levels rise, SIRT1-mediated deacetylation of PGC-1alpha increases, promoting new mitochondrial formation and improved oxidative capacity.

PARPs (poly-ADP-ribose polymerases) consume NAD+ to repair DNA breaks. After genotoxic stress, PARP1 activation can drain the cellular NAD+ pool rapidly; this is one reason PARP inhibitor cancer drugs work by keeping NAD+ low. Exogenous NAD+ supplementation directly opposes that mechanism.

CD38, an ectoenzyme that degrades NAD+, rises with age and is now recognized as a primary cause of age-related NAD+ decline. Direct IV or subcutaneous NAD+ administration bypasses the multi-step enzymatic conversion that oral precursors like NMN and NR require. It also supports the NAD+/NADH ratio in the electron transport chain, reducing electron leak and reactive oxygen species production.

NAD+ Benefits

  • NAD+ benefits center on cellular energy restoration, sirtuin activation, and DNA repair support.
  • Plasma NAD+ elevation of 398% above baseline after a single 6-hour IV infusion (2019 pilot study with metabolome tracking)[1].
  • Substance craving reduction from 5.9 to 0.22 on a 10-point scale in 50 patients using the BR+NAD IV protocol over 10 days [2].
  • Mid-afternoon energy crash elimination is the most consistently reported benefit across hundreds of user threads on r/Nootropics and r/longevity; users typically notice this within 3 to 6 weeks of subcutaneous dosing.
  • Exercise recovery improvement with reduced muscle soreness, reported at the intermediate dosing tier (250 mg, twice weekly); community users describe faster turnaround between training sessions.
  • Brain fog clearance, particularly in long COVID and chronic fatigue contexts, is one of the most frequently cited anecdotal benefits across peptide forums. Cognitive clarity tends to become more reliable by weeks 4 through 6.
  • Mitochondrial biogenesis support through SIRT1-mediated PGC-1alpha deacetylation, a mechanistically well-characterized pathway [4].

NAD+: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Moderate
Based on 10 key studies·Research only

IV NAD+ produces rapid, significant plasma elevation (up to 398% above baseline after 6-hour infusion)[1].

Dosing studied: 100–500 mg SubQ 2–3×/week (wellness); 500–1,500 mg/day IV × 10 days (addiction)
Read the evidence (key study, limitations)

IV addiction recovery protocol (BR+NAD) is the best-supported acute clinical use: PMID 36118157 (n=50) showed craving scores drop from 5.9 to 0.22 on 10-point scale. General anti-aging and wellness claims rest on mechanistic rationale (sirtuin activation, PARP substrate replenishment, mitochondrial biogenesis) with limited controlled human trial data. 2024 systematic review [3] confirms safety across clinical conditions but efficacy evidence remains heterogeneous.

Key Study

PMID 36118157: BR+NAD IV protocol in 50 SUD patients, 2022

Limitations

Most wellness/anti-aging trials are small (n<50), unblinded, or lack placebo control. IV plasma half-life is ~30–45 min: functional benefit persistence is mechanistically supported but not yet quantified with RCT rigor. No head-to-head SubQ vs IV outcomes RCT exists. Long-term safety of chronic SubQ administration unstudied.

Community Experience
Strong
4.0/5
Based on hundreds of threads across r/Nootropics (110k+ subs), r/longevity, r/Peptides

Highly positive overall.

Community dosing: 100–250 mg SubQ 2–3×/week maintenance; IV sessions 250–500 mg monthly or quarterly
Read the reports (what users report 5, common issues 5)

Energy uplift and mid-afternoon crash elimination are the most consistently reported benefits. Brain fog clearance, especially in long COVID and chronic fatigue contexts, is frequently cited. IV sessions praised for acute "reset" feeling. SubQ valued for practical, lower-cost maintenance between IV sessions.

What users report (5)
  • Mid-afternoon energy crash elimination
  • Cognitive clarity and reduced brain fog
  • Improved exercise recovery and reduced muscle soreness
  • Better sleep quality (especially first 2 weeks)
  • Long COVID and chronic fatigue symptom improvement (anecdotal, widely reported)
Common issues (5)
  • Cost: clinic IV sessions $250–$1,500+; home SubQ $150–$350/month compounded
  • Injection site sting (SubQ): intense if injected too quickly
  • Nausea, flushing, chest tightness during IV: rate-dependent and unpredictable
  • Quality risk: a 2025 compounded NAD+ endotoxin recall creates legitimate quality concern for home use
  • Debate about whether SubQ delivers equivalent outcomes to IV: not yet settled
Partially Aligned

Science and community converge on IV NAD+ for addiction/acute loading protocols. Community wellness use (SubQ maintenance, anti-aging) is driven by mechanistic extrapolation and self-reported outcomes rather than RCT evidence. Science has not refuted the wellness use case: data simply lags community adoption.

NAD+ Dosage Guide

CommunityCommunity dosing consensus from peptide research communities
LevelDose / InjectionFrequency
Beginner100 mg
2x/weekTrack
Moderate250 mg
2x/weekTrack
Aggressive500 mg
3x/weekTrack
Note:

Your 500 mg vial with 5 mL bacteriostatic water gives you 100 mg/mL. At 100 mg per dose, that's 1.0 mL (100 units on a U-100 insulin syringe), so one vial covers 5 doses. If you're running 250 mg doses, reconstitute with 2 mL instead: that gives 250 mg/mL, and each dose is 1.0 mL. Trying to pull 2.5 mL for a 250 mg dose from a standard 5 mL reconstitution is impractical for a single subcutaneous site.

Inject slowly. Thirty to sixty seconds minimum. The sting is the number one complaint in every forum thread, and speed is almost always the cause. Warm the syringe in your palm for a minute before injecting. Morning dosing is the standard; some users report sleep disruption with evening administration.

One thing most beginners miss: cloudiness or any visible precipitate means discard the vial. NAD+ degrades with heat and agitation. Add the water slowly down the vial wall and swirl gently. Never shake it.

Cycling Protocol

On Period
8 weeks
Off Period
2 weeks

Some protocols run continuously at maintenance doses. Higher-dose IV protocols are typically done in short bursts (3-5 days). Subcutaneous dosing can be sustained longer with periodic breaks.

Calculate your NAD+ dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

NAD+ Protocols by Goal

beginnerCommunity8 weeks on, 2 weeks off
Titration
Wk 1–2
50 mg · 2×/week · SubQ
Maintenance
Wk 3–8
100 mg · 2×/week · SubQ

Expected: Improved energy, reduced brain fog, better sleep quality; cognitive benefits more consistent by week 4–6

Monitor: No formal monitoring required at this dose for healthy adults; diabetics should track fasting glucose

How to Use NAD+

  1. 1
    Step 1

    Gather your supplies: 500 mg NAD+ lyophilized vial, bacteriostatic water, alcohol swabs, 27 to 31 gauge insulin syringe (U-100).

  2. 2
    Step 2

    Reconstitute: add 5 mL bacteriostatic water slowly down the inside wall of the vial. Swirl gently until fully dissolved. This gives 100 mg/mL. For higher concentration, use 2 mL water for 250 mg/mL.

  3. 3
    Step 3

    Draw your dose: for 100 mg, pull to the 100 unit mark (1.0 mL). For 250 mg from a 250 mg/mL reconstitution, pull to the 100 unit mark (1.0 mL). For 50 mg titration dose, pull to the 50 unit mark (0.5 mL from 100 mg/mL solution).

  4. 4
    Clean the injection site with an alcohol swab

    Abdomen (2 inches from the navel) or upper outer thigh. Rotate sites each injection.

  5. 5
    Step 5

    Pinch the skin, insert the needle at a 45 to 90 degree angle, and inject slowly over 30 to 60 seconds. Slow injection is the single most important factor for reducing the sting.

  6. 6
    Dispose of the syringe in a sharps container

    Do not recap.

  7. 7
    Step 7

    Store the reconstituted vial refrigerated at 2 to 8 degrees Celsius. Use within 28 days. Never freeze reconstituted NAD+.

  8. 8
    Timing: morning administration is standard

    Dose twice weekly for the beginner protocol (100 mg) or twice weekly for intermediate (250 mg).

Alternative Routes

Intravenous (IV) infusion

Higher peak plasma concentrations achievable (398% above baseline, PMID 31572171); faster onset; more pronounced subjective response; IV plasma t½ ~30–45 min so effect duration tied to infusion duration

Standard clinic IV dose 250–500 mg over 2–4 hours; addiction protocol 500–1,500 mg/day over 5–10 hours. Rate-dependent side effects (nausea, flushing) managed by slowing infusion.

Subcutaneous (SubQ)

Slower absorption through adipose tissue; lower, sustained delivery profile; near-100% bioavailability (bypasses GI first-pass metabolism); fewer acute side effects than IV

Volume limit ~1 mL per injection site; doses >100 mg require more concentrated reconstitution (2 mL BAC water instead of 5 mL) or split injections. 500 mg vial + 5 mL BAC water = 100 mg/mL; + 2 mL = 250 mg/mL.

Intramuscular (IM)

Faster absorption than SubQ; similar bioavailability; not studied head-to-head with SubQ for NAD+

Community use documented but less prevalent than SubQ; deltoid or gluteal injection typical; same dosing as SubQ generally applied

Oral (NMN or NR precursors: not NAD+ itself)

Oral NAD+ has poor bioavailability; oral precursors NMN/NR undergo multi-step enzymatic conversion and achieve lower peak plasma NAD+ elevations vs injection. 2026 study (PMID 41704678) showed similar tolerability between IV NAD+ and IV NR but did not compare SubQ vs oral outcomes

Cost-effective for long-term maintenance (~$50–$150/month vs $150–$350/month compounded SubQ); many users bridge between injectable cycles with oral NMN 500 mg or NR 300–1,000 mg/day. NOT equivalent for addiction recovery protocols.

Mixing your own vial? Use the NAD+ reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

NAD+ Stacking Protocols

How much does NAD+ cost?

Typical price

$0.11 to $0.16 per mg

Typical $0.132

Middle half of 114 US prices for 500 mg vials · read Oct 31

See prices

Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.

Compounded
$150–$350/month for home SubQ (20–30 injections at 100–250 mg; compounding pharmacy)

Pricing updated 2026-04-09

NAD+ Side Effects

The most serious safety concern with injectable NAD+ is endotoxin contamination. A compounding pharmacy issued a Class I recall in October 2025 covering its 100 mg/mL and 200 mg/mL NAD+ vials for raised endotoxins; a Class II recall for sterility assurance concerns preceded it in July 2025. Fever or rigors within one to two hours of injection are sentinel signs of endotoxin exposure. Stop immediately, do not reuse the vial, and seek medical evaluation.

IV infusion side effects are rate-dependent. Nausea, flushing, chest tightness, and headache occur during the drip and are directly proportional to the infusion speed. Slowing the rate resolves symptoms within minutes in most cases. These are not allergic reactions and do not indicate a defective product. During the BR+NAD addiction protocol (500 to 1,500 mg/day over 5 to 10 hours), these effects are expected and managed by the supervising clinician.

Subcutaneous injection stinging is the most common complaint at the home-use level. Injecting slowly over 30 to 60 seconds, warming the solution to room temperature, and using a 27 to 31 gauge insulin syringe all reduce the discomfort. Some injection sites are worse than others; rotating between abdomen and upper thigh helps.

Published side effect data beyond the above is limited. The 2024 systematic review [3] confirmed safety across clinical conditions but noted the total number of rigorously studied humans remains small. Most wellness and anti-aging trials have fewer than 50 participants, and many lack placebo controls.

Theoretical concerns exist around sustained supraphysiologic PARP and CD38 activation at high chronic doses. No hepatotoxicity has appeared in trials, but safety data for long-term subcutaneous use does not exist. Liver enzymes (ALT and AST) should be checked at baseline and at 8 weeks for anyone dosing at 250 mg or above per session.

NAD+ may support rapidly dividing cells. No data exists on its effects in active cancer or a history of malignancy. It should not be combined with PARP inhibitor drugs (olaparib, niraparib, rucaparib), as exogenous NAD+ directly counteracts their mechanism of action. Pregnancy and breastfeeding are absolute contraindications since no safety data exists for injectable NAD+ in those populations.

Common Issues & Solutions

Severe injection site sting: Inject over 30–60 seconds (not faster); warm the solution to room temperature before injection; use a 27–31g insulin syringe; try a different abdominal injection site.

Nausea/flushing during IV: Rate-dependent: slow the infusion immediately; symptoms should resolve within minutes of reducing the drip rate; this is not a dangerous reaction or product quality issue.

No perceived effect at 100 mg SubQ: IV plasma half-life is only ~30–45 min; SubQ provides a slower, sustained delivery: subjective effects are subtler than IV; allow 4–6 weeks before judging; check reconstitution integrity (swirl gently, never shake; cloudiness means discard).

Fever or rigors after injection: Stop immediately and do not use the same vial again: this pattern is consistent with endotoxin contamination (see the 2025 Class I recall); contact the pharmacy; seek medical evaluation.

Reconstitution cloudiness or precipitate: NAD+ is heat- and agitation-sensitive; add BAC water slowly down the vial wall and swirl gently; cloudiness indicates degradation: discard.

Ask AI about this page

Ask AI for a second opinion on NAD+ dosing and side effects

Contraindications

  • Pregnancy or breastfeeding: no safety data available for injectable NAD+
  • Active cancer or history of malignancy: NAD+ may support rapidly dividing cells; effects on tumors not studied
  • Known hypersensitivity to NAD+ or nicotinamide derivatives
  • Severe cardiovascular disease: IV infusion may cause transient hemodynamic changes
  • Children and adolescents under 18: not studied in pediatric populations

Drug Interactions

  • Chemotherapy agents: NAD+ may affect PARP inhibitor efficacy (e.g., olaparib, niraparib) by restoring NAD+ that PARPi drugs aim to deplete
  • Blood pressure medications: IV NAD+ may cause transient changes in heart rate and blood pressure; monitor closely
  • Immunosuppressants: NAD+ modulates inflammatory pathways via sirtuin activation; potential interaction with immunomodulatory drugs
  • Alcohol and sedatives: NAD+ is consumed during alcohol metabolism via alcohol dehydrogenase; concurrent heavy alcohol use may blunt therapeutic benefit
  • Diabetes medications: NAD+ influences glucose metabolism through SIRT1/AMPK pathways; monitor blood glucose when combining
  • PARP inhibitors work by depleting cellular NAD+: exogenous NAD+ supplementation directly counteracts their mechanism of action and may reduce efficacy in cancer treatment

Product Quality

Recommended Monitoring

TestWhenTarget
Liver enzymes (ALT, AST, GGT)Baseline before starting; at 8 weeks for doses ≥250 mg/sessionALT <40 U/L, AST <40 U/L (reference lab ranges)
Fasting glucose / HbA1cBaseline and at 8 weeks for diabetics or pre-diabeticsPer individual clinical targets
Blood pressure and heart rateDuring every IV infusion sessionBP <140/90 mmHg; HR 60–100 bpm during infusion
Post-injection endotoxin reaction screeningFirst 2 hours after injection with each new vial batchNot listed
Liver enzymes (ALT, AST, GGT)

High-dose NAD+ drives PARP and sirtuin activity; theoretical hepatic load at sustained supraphysiologic doses; no established hepatotoxicity in trials but safety data is limited

Fasting glucose / HbA1c

NAD+ influences glucose metabolism through SIRT1/AMPK pathways; diabetics on insulin or sulfonylureas should monitor for additive glucose-lowering effect

Blood pressure and heart rate

IV NAD+ at high infusion rates may cause transient hemodynamic changes; elevated cardiovascular risk warrants monitoring

Post-injection endotoxin reaction screening

Active 2025 recall history for NAD+ injectable products; endotoxin reactions (fever >38°C, rigors, chills) occur within 1–2 hours of contaminated injection

NAD+ Before and After

Day 1-3
IV loading

Immediate increase in plasma NAD+ levels (up to 398% above baseline after 6-hour infusion). Some users report improved mental clarity and energy within hours. Nausea, flushing, or chest tightness may occur during infusion.

Weeks 1-2
SC maintenance

Transition to subcutaneous injections. Injection site stinging is common but manageable with slow administration. Early reports of improved sleep quality and reduced brain fog.

Weeks 3-6

Sustained energy improvements and better exercise recovery. Cognitive benefits become more consistent. Cellular NAD+ pools are being replenished through ongoing supplementation.

Weeks 7-12

Full benefits are realized including improved mitochondrial function, steady energy levels, and enhanced mental performance. Users in addiction recovery protocols often report reduced cravings at this stage.

Ongoing maintenance

Lower-frequency dosing (1-2x/week) to maintain elevated NAD+ levels. Periodic IV booster sessions every 1-3 months are used in some longevity protocols. Benefits are sustained with consistent use.

What to Expect

Day 1 through 3 (IV loading session): Plasma NAD+ can spike to 398% above baseline during a six-hour IV infusion [1]. Many users report a "clean" energy uplift and improved mental clarity within hours of the session. Nausea, flushing, and chest tightness are common during the drip and directly tied to infusion speed; slowing the rate resolves them within minutes.

Weeks 1 through 2 (SubQ maintenance start): The injection sting dominates the early experience. Slow administration over 30 to 60 seconds makes it manageable. Improved sleep quality is one of the first benefits users notice, often within the first week or two. Some report reduced brain fog during this window. Cellular NAD+ pools are beginning to replenish; sirtuin and PARP activity increases at the tissue level.

Weeks 3 through 6: Energy improvements become more consistent and the mid-afternoon crash most users complain about tends to disappear. Exercise recovery speeds up noticeably. Cognitive benefits get more reliable rather than intermittent. Side effects typically diminish as injection technique improves.

Weeks 7 through 12: This is where the full protocol payoff arrives. Mental performance, steady energy, and physical recovery all hit their peak according to community reports. Users in addiction recovery protocols report sustained craving reduction at this stage. Sirtuin-mediated deacetylation of PGC-1alpha is driving mitochondrial biogenesis; PARP-mediated DNA repair efficiency has improved with sustained NAD+ availability.

Ongoing maintenance and off weeks: NAD+ levels drift back toward baseline during the two-week break. Some functional benefits persist due to epigenetic changes from sirtuin activation, but substrate-dependent enzymatic activity wanes. Many users run continuous low-dose maintenance at 100 mg once weekly. Others stick to strict 8-on, 2-off cycling. Quarterly IV booster sessions at a clinic are common in longevity protocols.

Detailed Timeline: Science vs Community

Day 1–3 (IV loading session)
Science

Plasma NAD+ up to 398% above baseline after 6-hour IV infusion (PMID 31572171); rapid tissue uptake; plasma clearance t½ ~30–45 min so functional levels maintained during multi-hour infusion

Community

Many users report improved mental clarity and elevated mood within hours of IV session; energy uplift described as "clean": not stimulant-like

Weeks 1–2 (SubQ maintenance start)
Science

Cellular NAD+ pools begin replenishment; sirtuin and PARP activity increases; mitochondrial biogenesis markers upregulated

Community

Injection site sting is the dominant early experience; improved sleep quality frequently noted in week 1–2; some report reduced brain fog

Weeks 3–6
Science

Sustained elevation of tissue NAD+ levels with consistent dosing; improved NAD+/NADH ratio supports oxidative phosphorylation efficiency

Community

Energy improvements become more consistent; exercise recovery noticeably faster; mid-afternoon energy crash eliminated for most users; cognitive benefits more reliable

Weeks 7–12
Science

Maximal sirtuin-mediated deacetylation effects; PGC-1α upregulation supports mitochondrial biogenesis; PARP-mediated DNA repair efficiency improved

Community

Peak subjective benefit period; improved mental performance, steady energy, and enhanced physical recovery all reported; addiction recovery users report sustained craving reduction

Ongoing maintenance / off weeks
Science

NAD+ levels return toward baseline during off weeks; functional benefits partially persist due to epigenetic changes (sirtuin-mediated) but substrate-dependent enzymatic benefits wane

Community

Some users run continuous low-dose (100 mg 1×/week); others prefer strict 8-on/2-off cycling; quarterly IV booster used in longevity clinic protocols

Pharmacokinetics

Half-Life
N/A
Bioavailability
IV: 100%; SC: not formally quantified but bypasses first-pass metabolism; Oral NAD+ has poor bioavailability
Tmax
~2-6 hours (IV infusion dependent on rate); SC: ~30-60 minutes
Data Confidence
low

Source: No plasma half-life has been measured. In a 6-hour IV infusion (3 μmol/min), plasma NAD+ and its metabolites did not rise for the first 2 hours; infused NAD+ was rapidly and completely removed (PMID 31572171).

Pharmacokinetics: Active Dose Over Time

t½ = Not measured (infused NAD+ is cleared from plasma rapidly; functional effects reported for 2-4 hours)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Molecular Weight
663.43 Da
Formula
C21H27N7O14P2
Type
Small Molecule
Identifiers

Who Should Consider NAD+

  • Adults over 40 experiencing age-related NAD+ decline and fatigue
  • Individuals seeking cognitive support and mental clarity
  • People in addiction recovery programs (NAD+ IV protocols)
  • Athletes wanting improved mitochondrial function and recovery
  • Patients with chronic fatigue or mitochondrial dysfunction
  • Adults interested in longevity and sirtuin activation

Related Peptides

What Changed for NAD+

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 202610 Citations

References

  1. [1]A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+ (Front Aging Neurosci 2019) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Nicotinamide adenine dinucleotide (NAD+) and enkephalinase inhibition infusions significantly attenuate psychiatric burden sequelae in substance use disorder (Blum et al., Curr Psychiatry Res Rev 2022) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Evaluation of Safety and Effectiveness of NAD in Different Clinical Conditions: A Systematic Review (Am J Physiol 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]NAD+ and Sirtuins in Aging and Disease (Trends Cell Biol 2014) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Resources

Related Tools

Storage & Stability

Before Reconstitution
Room temperature up to 1 month, refrigerated up to 12 months
After Reconstitution
Refrigerate at 2-8°C, use within 4 weeks
Temperature
2-8°C (36-46°F) after reconstitution

Frequently Asked Questions

SubQ bioavailability is near 100% since it bypasses the GI tract entirely. The slower absorption through fat tissue actually reduces the nausea and flushing you get with IV drips. IV produces faster, higher peak levels useful for acute protocols like addiction treatment. For ongoing maintenance, SubQ is practical and effective.

The BR+NAD protocol delivers 500-1,500 mg/day IV over 5-10 hours for 10 consecutive days with amino acids and B-vitamins. A 2022 study (PMID 36118157) with 50 substance use patients showed craving scores dropping from 5.9 to 0.22 out of 10: that's dramatic. This is the best-supported acute clinical use of IV NAD+.

Nausea, flushing, and chest tightness are rate-dependent side effects from supraphysiologic extracellular NAD+. They're directly proportional to how fast the drip runs. Slow the infusion rate and symptoms typically resolve within minutes. It doesn't mean the product is bad or that you're having a dangerous reaction.

For acute loading, IV NAD+ wins: one study showed 398% above baseline (PMID 31572171). But for chronic maintenance, oral NMN or NR may achieve similar steady-state levels at a fraction of the cost. A 2026 head-to-head study (PMID 41704678) showed similar tolerability between IV NAD+ and IV NR. The honest answer is the debate isn't settled yet.

Use bacteriostatic water (not sterile water), inject it slowly down the vial wall, and swirl gently: never shake. Use a 27-31g insulin syringe, inject SubQ into abdomen or upper thigh over 30-60 seconds to minimize the sting. Refrigerate at 2-8 degrees C and toss it after 28-30 days. Never freeze reconstituted solution.